Using optical imaging to monitor breast cancer treatment response
Optical Monitoring of Neoadjuvant Chemotherapy and Prediction of Pathological Complete Response in Breast Cancer Patients
This study is testing a new imaging method to see how well chemotherapy is working for women with breast cancer, so doctors can adjust treatments if needed.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | IRCCS San Raffaele Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Milan) |
| Trial ID | NCT04767659 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate a new optical imaging technique to monitor the effectiveness of neoadjuvant chemotherapy (NAC) in women with breast cancer. The approach involves using near-infrared spectroscopic imaging to non-invasively assess changes in tumor size, vascularization, and blood oxygenation during treatment. By identifying patients who do not respond to NAC early on, the study seeks to tailor medical and surgical interventions more effectively. The trial will enroll twenty adult women diagnosed with breast cancer who are candidates for NAC at the San Raffaele Hospital in Milan.
Who should consider this trial
Good fit: Ideal candidates for this study are women over 18 years old with a recent diagnosis of breast cancer who are eligible for neoadjuvant chemotherapy.
Not a fit: Patients who are pregnant, breastfeeding, or have distant metastasis will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment plans for breast cancer patients, reducing unnecessary exposure to ineffective chemotherapy.
How similar studies have performed: While there have been studies using imaging techniques in breast cancer treatment, this specific optical imaging approach is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women above 18 years of age * Women with a recent diagnosis of breast cancer candidate for neoadjuvant chemotherapy * Women willing to give informed consent Exclusion Criteria: * Subject is pregnant or breastfeeding * Subject is unable or unwilling to give informed consent * Previous surgery of the same breast * Presence of distant metastasis * Breast implants
Where this trial is running
Milan
- Ospedale San Raffaele — Milan, Italy (Recruiting)
Study contacts
- Principal investigator: Panizza — IRCCS San Raffaele
- Study coordinator: Pietro Panizza, Pi
- Email: panizza.pietro@hsr.it
- Phone: 02-26436310
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.